Eight (6.6%) patients were temporarily dropped out of cancer treatment because of cardiotoxicity, mean LVEF 48.3% ± 6.8%, while on anti-HER2 therapy, and half of these patients had previous therapy with anthracyclines. Here, ERBB2 is linked to cancer.